Perspective: New Alzheimer’s Drug is Projected to Increase National Health Expenditures by More Than One Percent
06/17/2021
On June 7, the U.S. Food and Drug Administration (FDA) approved Aduhelm for treatment of Alzheimer’s disease. While Biogen, the drug’s manufacturer, tested it on patients with mild cognitive impairment (of whom there are an estimated one to two million in the U.S.), the FDA approved its use more broadly for the more than 6 million Americans currently diagnosed with Alzheimer’s. The drug is administered through intravenous infusion at an annual cost of $56,000 per patient – a non-retail expenditure that will be borne primarily by Medicare Part B.
Read MoreWhere is the medical cost trend headed in 2022?
06/11/2021
PwC's Health Research Institute (HRI) is projecting a 6.5% medical cost trend in 2022, slightly lower than the 7% medical cost trend in 2021 and slightly higher than it was between 2016 and 2020. Healthcare spending is expected to return to pre-pandemic baselines with some adjustments to account for the pandemic’s persistent effects.
Read MorePCI Welcomes Jason Benjamin
08/16/2019
Pennsylvania Chamber Insurance is pleased to welcome Jason Benjamin, Benefits Consultant in the Lehigh Valley where he is responsible for service and retention of PCI’s existing insurance customers, and to affirm a customer-centric presence in the eastern region of the state. He works in tandem with the PCI sales team to ease the transition for oncoming prospects to satisfied customers. As a previous long-standing member of the PCI team, Jason returns after working with Kistler Tiffany Benefits.